/
OCS
$12.82-$0.07 (-0.54%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$715.8M
56M shares
52-week range
$10.52 – $34.48
10% from low
Exchange
NASDAQ
CS
Change+$1.93
Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
www.oculis.com- Employees
- 60
- IPO / List date
- Mar 3, 2023
Held by traders on TradeandTell
No one on the platform currently holds OCS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in OCS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OCS yet.
